Introduction: Chronic spontaneous urticaria (CSU) is a common and hard to treat
statistical analyses were descriptive.
Results: The majority of the 660 patients screened to be treated (median age 44 years, IQR = 31-59 years, n = 654) received rupatadine 10 mg tablets once (477 patients) or twice (105 patients) daily for a median time of 28 days. After treatment, 93.2% of the patients (606/650) reported a clear overall improvement of symptoms. Rupatadine significantly reduced the urticaria activity score (UAS7) as well as the frequency and severity of existing angioedema episodes. Similarly all domains of the urticaria-specific
INTRODUCTION
Chronic spontaneous urticaria (CSU) is one of the most common and disturbing cutaneous conditions. CSU is characterized by the daily or almost daily reoccurrence of pruritic wheals, angioedema, or both, for more than 6 weeks [1] . In the majority of cases, the underlying cause remains unidentified [1, 2] . The condition often lasts for years [1, 2] . Besides being bothersome and debilitating, CSU has a proven substantial negative impact on quality of life (QoL) of affected individuals [2] [3] [4] [5] [6] [7] . Treatment, which is almost always provided on an outpatient basis, is still a challenge. The first line treatment of CSU, according to the recommendations of the current EAACI/GA 2 LEN/EDF/WAO urticaria guideline [1] , is the continued use of non-sedating, second-generation antihistamines (nsAHs). These drugs have been shown to be efficacious and safe in numerous clinical trials, but real-life data from the use of these drugs in routine clinical care are limited. This is especially true for newer nsAHs such as rupatadine.
Rupatadine, an N-alkyl pyridine derivative, is a selective oral histamine H 1 -receptor inverse agonist, indicated for symptomatic treatment of allergic rhinitis and urticaria in adults and children C2 years [8, 9] . The drug exhibits strong and balanced antagonist activities towards both histamine H 1 -and platelet-activating factor (PAF) receptors (for review see: [10] [11] [12] [13] [14] [15] [16] ). Both histamine and PAF are held to importantly contribute to the signs and symptoms of CSU, i.e., itchy wheals and angioedema [17] . Moreover, rupatadine has a broad profile of anti-inflammatory effects by inhibiting both inflammatory cells and a range of mediators involved in the early-and late-phase inflammatory responses [10, 18, 19] .
After oral administration, rupatadine shows a fast onset of action, producing rapid symptomatic relief, and a long-lasting ( [24 h) clinical activity, which allows administration once a day [12, 20] . Rupatadine has undergone long-term testing (up to 1 year) in compliance with ICH and EMA guidelines confirming its good safety profile [21] [22] [23] . At the licensed daily oral dose of 10 mg, rupatadine has no clinically relevant effects on the cardiovascular system, cognitive function or psychomotor function [10, 14] . The current guideline on the management of urticaria patients recommends aiming for a complete symptom relief [1] . However, many patients fail to get satisfactory relief with the licensed doses [1, 2] . In this case, the European guideline advises to progressively increase the conventional dosages of oral nsAHs up to fourfold in poorly responding patients [1] . 
METHODS

Study Design
This multicenter, open, prospective, non-interventional, observational trial was conducted by 146 dermatologists in private practices in Germany from April 1, 2011 until June 30, 2011 (last day of recruitment). The rupatadine therapy was prescribed by the participating physicians in the course of normal outpatient care, was commercially available and funded according to local practice in usual routine care. The study protocol, therefore, did not contain any specifications regarding dosing of rupatadine or duration of treatment. Instead, the advising dermatologists were asked to follow the recommendations defined in the licensed approval from the national regulatory authorities. The contraindications, special warnings and precautions for use, interactions, information on use during pregnancy and lactation, effects on ability to drive and use machines, and desirable effects specified in the Summary of Product Characteristics (SmPC) had to be observed. Prior to the start of this study, all participating physicians were instructed in the conduct and documentation of the trial.
Compliance with Ethics
This non-interventional, observational trial conformed with § 67 (6) GmbH, Bamberg, Germany, [8] ) was prescribed by the attending physician, were eligible to enter the trial. Any current and prior medications were acceptable for their inclusion. Participants were free to withdraw at will at any time. If they were or decided to withdraw from the study, the reason for discontinuation had to be specified.
The sample size of this trial was formed through the number of patients that were treated during the predetermined study period by any of the participating dermatologists.
Assessments and Outcome Measures
There were no defined study-related procedures; 
RESULTS
Trial Population and Patient Baseline Characteristics
The data of all 660 participants included in this study were entered into the safety analysis.
According to the observational plan, one patient was excluded from the evaluation of efficacy due to a treatment period of less than 7 days, leaving 659 patients for the efficacy analysis set. Out of the 660 patients, 422 (63.9%) were females and 235 (35.6%) were males, while for 3 subjects (0.5%) respective information was missing. The median age of the patients was 44 years (range 9-92 years, IQR 31-59 years, n = 654), and the median body weight 73 kg (range 44-220 kg, IQR 65-82 kg, n = 657). 
Global Assessment of Effectiveness and Tolerability
According to the observational study protocol, the data of 651 patients/physicians were considered relevant for overall assessment of treatment effectiveness. Figure 3a (Fig. 3b) .
The question relating to therapy continuation with rupatadine was answered affirmatively for 367 out of 648 patients (56.6%) and negated for 276 patients (42.6%)
by the physicians after the observational period. The standard recommended daily dose of 10 mg of rupatadine was the most frequently prescribed dosage (271/367, 73.8%).
Therapy Withdrawals and Adverse Events
Treatment with rupatadine was prematurely terminated in 39 out of 660 (5.9%) patients.
Reasons for withdrawal were lack of efficacy (20/ 39), AEs (7/39) and ''other'' (6/39) including 5
cases of nonattendance at the final visit, or not drug related (4/39); for 2 patients respective information was missing.
Overall, 21 out of the 660 (3.2%) patients experienced 27 AEs during rupatadine treatment. The most frequently reported AEs with an at least possible causal relationship were fatigue (n = 11), headache (n = 3) and nausea (n = 3). Treatment with the study drug was discontinued in 11 out of the 21 patients with an AE, and in 10 cases medication was maintained.
DISCUSSION
To our knowledge this is the first observational, non-interventional study to demonstrate the effectiveness and favorable tolerability of oral rupatadine administered according to the established dosage recommendations in the treatment of CSU in routine outpatient care.
As CSU has a detrimental effect on both objective functioning and subjective well-being [1, 2, 4-7, 10], evaluation of urticaria activity is Fig. 1 UAS7 score before and after treatment with rupatadine (n = 622). The bottom and the top of each notched box are the first and third quartiles, and the line inside the box is the median. The whiskers represent the lowest extreme value limit still within 1.5 9 IQR subtracted from the lower quartile, and the upper extreme value limit still within 1.5 9 IQR added to the upper quartile. Stars mark extreme values which are either 1.5 9 IQR or more above the third quartile or 1.5 9 IQR or more below the first quartile, but which are not indicated as outliers. The notch around the median offers a rough approximation to the 95% confidence interval of the median. The computed p value for the observed or a more extreme pre-versus post-treatment difference is p\0.001 (Wilcoxon signed rank test). IQR interquartile range just as important to be looked at as assessment of the impact of the disease on patients' QoL.
Therefore, two validated and disease-specific tools for patient-reported outcomes assessment were used in the present study: the UAS7 score for symptoms and the Cu-Q 2 oL questionnaire for urticaria-related QoL impairment. Noting the changes in frequency and severity of itchy wheals as well as of angioedema episodes is a useful way of evaluating clinical efficacy [1] .
The relevant differences in CSU activity, observed in the present trial after a median treatment period of 28 days and determined through the use of the UAS7 and the angioedema score, indicated that an oral dose of 10 mg rupatadine, administered once or twice daily, produced obvious improvements in the clinical status of the affected patients.
These results are in line with the clinical evaluations, on which approval for the drug was granted. The efficacy of rupatadine in the treatment of moderate-to-severe CSU was evaluated in two randomized, double-blind, placebo-controlled multicentre studies [26, 27] . Both trials showed that rupatadine 10 mg and 20 mg per day rapidly and significantly reduced urticaria symptoms and improved health-related QoL of these patients. A pooled responder analysis of both studies highlighted the greater improvements when using the higher dosage of 20 mg rupatadine daily [24] : evaluating disease activity by use of the UAS a significant reduction of at least 75% in the 10 mg (34.8%) and 20 mg (48%) rupatadine groups as compared to 13.9% in the placebo group (p\0.0001) was demonstrated. In the The majority of the patients in our study (77.9%) were using the approved (standard) dose of the drug (10 mg of rupatadine once daily) which is defined in the current SmPC [8] . 
